Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So. [Yahoo! Finance]
Roivant Sciences Ltd. (ROIV)
Company Research
Source: Yahoo! Finance
The healthcare company's innovative Spikevax was one of the go-to vaccines that sped to market, not only protecting hundreds of millions of people from COVID-19, but also producing gobs of revenue and healthy profits. That was a hard act to follow, and ever since the public health crisis ended, Moderna's stock has languished. One Wall Street analyst recently cut her price target on the stock, reiterating her sell recommendation at the same time. The company isn't so healthy these days Wolfe Research's Alexandria Hammond now feels Moderna will be trading at around $25 per share a year from now, well down from her previous price target of $35. That new level is 30% below the pharmaceutical stock's closing price Tuesday. Hammond kept her underperform (read: sell) rating on the stock intact. According to reports, Hammond's latest take on Moderna was based on issues such as cost-management struggles, and legal headaches due to a long-running patent infringement lawsuit brought agai
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Immunovant (IMVT) Is Up 14.0% After Roivant-Backed $550 Million Equity Raise For IMVT-1402 - Has The Bull Case Changed? [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences (NASDAQ:ROIV) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $24.00 to $33.00. They now have a "buy" rating on the stock.MarketBeat
- Roivant Sciences (NASDAQ:ROIV) had its "outperform" rating reaffirmed by analysts at Leerink Partners.MarketBeat
- Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor DayGlobeNewswire
ROIV
Earnings
- 11/10/25 - Beat
ROIV
Sec Filings
- 12/15/25 - Form 4
- 12/15/25 - Form 144/A
- 12/15/25 - Form 144
- ROIV's page on the SEC website